[ RadSafe ] New oral agents may prevent injuryafterradiationexposure
cary.renquist at ezag.com
Mon Jul 13 16:45:08 CDT 2009
Franz, excellent proposal....
Since fruit is a good source of antioxidants, might as well combine 1) & 2) and add a little bamboo umbrella (Caribbean music is optional)
I'm off to write-up a grant proposal...
cary.renquist at ezag.com
From: radsafe-bounces at radlab.nl [mailto:radsafe-bounces at radlab.nl] On Behalf Of Franz Schönhofer
Sent: Monday, 13 July 2009 13:49
To: 'Brennan, Mike (DOH)'; radsafe at radlab.nl
Subject: AW: [ RadSafe ] New oral agents may prevent injuryafterradiationexposure
Dear Mike and RADSAFErs,
My comment is in two parts, please be careful to read them separately....
1) I cannot judge anything from the release, because it does not give any
details. The "antioxidants" seem to be very popular, you will find them in
any pills for loosing weigh over antiaging forumlas - ok, now we find them
as anti-dirty bomb formulas - regardless whether tritium, Co-60, Iridium,
Tc-99m, Pu-239 or whatsoever available in a wide spectrum might be released.
There have been many very reasonable scenarios on RADSAFE showing the very
limited impact of dirty bombs on the population, which I full<y support and
am convinced. It is an old method to frighten people to receive support for
2) Many decades ago I remember that it was distributed on our massmedia,
that ethyl alcohol (C2H5OH) was an excellent scavenger for free radicals. We
joked then, that if it would not really help to remediate the radiation
impact it would at least help to feel the "patient" better... Is this nasty?
Franz Schoenhofer, PhD
Von: radsafe-bounces at radlab.nl [mailto:radsafe-bounces at radlab.nl] Im Auftrag
von Brennan, Mike (DOH)
Gesendet: Montag, 13. Juli 2009 19:13
An: radsafe at radlab.nl
Betreff: RE: [ RadSafe ] New oral agents may prevent injury
If they do a well designed and impartially run double-blind study, and
it supports their claims, I will be impressed. Until then, I am
From: radsafe-bounces at radlab.nl [mailto:radsafe-bounces at radlab.nl] On
Behalf Of ROY HERREN
Sent: Sunday, July 12, 2009 11:44 PM
To: radsafe at radlab.nl
Subject: [ RadSafe ] New oral agents may prevent injury after
Public release date: 10-Jul-2009
Contact: Allison Rubin
allison.rubin at gmail.com
Boston University Medical Center
New oral agents may prevent injury after radiation exposure
(Boston) - Researchers from Boston University School of Medicine (BUSM)
and collaborators have discovered and analyzed several new compounds,
collectively called the ''EUK-400 series,'' which could someday be used
to prevent radiation-induced injuries to kidneys, lungs, skin,
intestinal tract and brains of radiological terrorism victims. The
findings, which appear in the June issue of the Journal of Biological
Inorganic Chemistry, describe new agents which can be given orally in
pill form, which would more expedient in an emergency situation.
These agents are novel synthetic "antioxidants" that protect tissues
against the kind of damage caused by agents such as "free radicals."
Free radicals, and similar toxic byproducts formed in the body, are
implicated in many different types of tissue injury, including those
caused by radiation exposure. Often, this kind of injury occurs months
to years after radiation exposure. The BUSM researchers and their
colleagues are developing agents that prevent injury even when given
after the radiation exposure.
This paper describes a newer class of compounds, the ''EUK-400 series,''
that are designed to be given as a pill. According to the researchers,
experiments described in their paper prove that these agents are orally
active. They also show that the new agents have several desirable
"antioxidant" activities, and protect cells in a "cell death" model.
These same BUSM researchers and collaborators had previously discovered
novel synthetic antioxidants that effectively mitigate radiation
injuries, but had to be given by injection. "We have developed some of
these agents and have studied them for over 15 years beginning with our
work at the local biotechnology company Eukarion," said senior author
Susan Doctrow, PhD, a research associate professor of medicine at BUSM's
Pulmonary Center. "These injectible antioxidants are very effective, but
there has also been a desire to have agents that can be given orally. A
pill would be more feasible than an injection to treat large numbers of
people in an emergency scenario," she adds.
Future studies will focus on the EUK-400 compounds' effects in various
experimental models for radiation injury. Data showing their benefits in
models for radiation injury in blood vessel cells have been presented at
two major scientific conferences and will be the topic of future
publication. More broadly, beyond the potential for treating victims of
radiological terrorism, these compounds could also be useful drugs
against a variety of diseases where an effective antioxidant has
potential benefits, for example, various neurological, pulmonary,
cardiovascular, and autoimmune disorders. Previously, Doctrow's lab and
others have published studies showing that the injectible versions of
these compounds are beneficial in models for several such diseases.
Funding for this study was provided by the U.S. Centers for Medical
Countermeasures Against Radiation (CMCR) program, administered by
National Institute of Allergy and Infectious Diseases. The study was
initiated with CMCR "Pilot Grant" funding awarded to Dr. Rosalind
Rosenthal, first author of the paper and currently a research associate
at BUSM. Doctrow's laboratory at BUSM is a member of a five-institution
CMCR program, based at the Medical College of Wisconsin in Milwaukee.
More information about the RadSafe